Abbvie Inc
NYSE: ABBV
$214.47
+$2.70 (+1.3%)
Closing Price on March 17, 2025
ABBV Articles
In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster Humira being approved took the backseat to many other things.
Published:
Last Updated:
Most Wall Street strategists agree that the way to play the fourth quarter and next year is with large cap stocks that pay and consistently increase their dividends.
Published:
Last Updated:
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apple, Callon Petroleum, Hewlett Packard Enterprise, Lululemon Athletica, Nike and Rio Tinto.
Published:
Last Updated:
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Published:
Last Updated:
Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for each of its large cap pharmaceutical stocks.
Published:
Last Updated:
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.
Published:
Last Updated:
In a recent research note, the analysts at Jefferies made a big move by adding Ball Corp. to the firm's well-respected Franchise Picks list of stocks to buy.
Published:
Last Updated:
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
Published:
Last Updated:
AbbVie released a better-than-expected second-quarter earnings report before the markets opened on Friday.
Published:
Last Updated:
Despite the fact that energy has tumbled 20% from the highs posted in June, Jefferies remains bullish on the natural gas arena, and with good reason.
Published:
Last Updated:
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.
Published:
Last Updated:
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
Published:
Last Updated:
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.